SecBot SecBot
424B5 ·Filed May 4, 2026

CABA

Cabaletta Bio, Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed6mo ago SEC0001193125-26-202441
Notable filing: 424B5
Actionable Insight ▼ Bearish

The massive ~51% dilution at a ~1.4% discount to the prior close ($2.90 vs $2.94) signals urgent capital needs despite the recent $117M cash balance. The company's auditor included a going concern qualification in the FY2025 10-K, and this offering only extends runway to mid-2027. Watch for potential further dilution as the company will likely need additional capital before reaching profitability. The 60-day lock-up expiration in early July 2026 could create additional selling pressure.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.83
T+0 close · May 4, 2026 · via day close
Latest settled
−31.59%
T+60 · $2.62
Vs SPY
−33.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $3.83entry
  2. T+1 · 7mo ago +8.36%α +7.56% · $4.15
  3. T+5 · 6mo ago −0.26%α −3.20% · $3.82
  4. T+20 · 6mo ago −4.18%α −9.82% · $3.67
  5. T+60 · 4mo ago −31.59%α −33.45% · $2.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cabaletta Bio is selling 51,725,000 shares of common stock at $2.90 per share in a dilutive follow-on offering, raising approximately $141 million in net proceeds. The offering represents a ~51% increase in shares outstanding (from ~100.5M to ~152.2M), creating immediate dilution of $1.30 per share for new investors. Proceeds will fund expanded clinical development of its lead CAR-T candidate rese-cel and manufacturing scale-up, extending cash runway into mid-2027.

Key Facts

  • Offering of 51,725,000 shares at $2.90 per share, raising $150M gross / ~$141M net proceeds
  • Shares outstanding will increase from ~100.5M to ~152.2M, a ~51% dilution
  • Immediate dilution of $1.30 per share for new investors (offering price $2.90 vs. as-adjusted book value $1.60)
  • Preliminary cash balance of ~$117M as of March 31, 2026; pro-forma cash ~$252.6M after offering
  • Cash runway extended into mid-2027; prior guidance had cash lasting into first half of 2026
  • Underwriters include TD Cowen, Guggenheim Securities, Cantor, and H.C. Wainwright
  • 60-day lock-up for insiders and company from pricing date (May 4, 2026)

Financial Impact

~$141M net proceeds raised; ~51% dilution to existing shareholders; immediate per-share dilution of $1.30

dilutioncash runwayshares outstanding

Risk Factors

  • Massive dilution (~51%) will pressure stock price as new shares hit the market
  • Going concern qualification from auditor indicates financial distress risk
  • Pre-revenue biotech with no approved products; clinical trial failures could destroy remaining value
  • Cash runway only extended to mid-2027; additional capital likely needed before profitability
  • Lock-up expiration in ~60 days could lead to insider selling overhang

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001193125-26-202441
Document: 0001193125-26-202441-index-headers.html0001193125-26-202441
Document: 0001193125-26-202441-index.html0001193125-26-202441
Document: 0001193125-26-202441.txt0001193125-26-202441

Track record

29 reports on CABA

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 4 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
  3. Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
  4. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
  5. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  6. Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
  7. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  8. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
  9. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
  10. Nov 5, 202611d ago Press Release Neutral 4/10 No price data
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026